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Abstract: 
The accounting information associated with clinical results is able to map the real cost efficiency in the 
clinical trial. The study analyzes explicitly the clinical trial carried out in 2017 by the "Bambin Gesù" 
Pediatric Hospital in Rome (Italy). The survey for the first time classifies the costs of a clinical trial on the 
use of micafungin in pediatric patients. The study provides an example of ways and items of expenses related 
to the clinical trial. The methodology used is applicable and can be used to compare future trials, thus 
identifying reference benchmarks. The study through practical application seeks to identify the correct 
method to avoid errors during the detection of clinical trials as evidenced by the study by Graves et al. 
(2002) through a proper application. The article also highlights the main cost items to be kept under control 
during the clinical trial phases. Moreover, given the incidence of candida in children, the study increases 
the literature on the administration and testing of specific drugs for treatment and therapy 
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Introduction 
Invasive candidiasis is a major cause of morbidity and mortality in intensive care healthcare settings and are 
largely associated with the use of invasive procedures and extensive use of new generation cephalosporins 
and other broad-spectrum antibiotics, essential for these delicate patients to survive. Therefore these 
infections are associated with technological and pharmaceutical progress in intensive medical care.  
In neonates, the most severe risk factor for candidiasis is prematurity because the related functional 
insufficiency of the immune system and invasive procedures performed in the context of neonatal intensive 
care units.  (Auriti, Falcone, et al., 2016). The incidence of the disease for newborns weighing less than 1000 
g at birth is around 10% (Bochennek et al., 2015). Mortality among infected neonates is very high: in the 
case of gestational age less than 28 weeks and birth weight lower than 1000 g the mortality rate is between 
40-50% of cases (Bochennek et al., 2015; Hope et al., 2010).  
In children up to 18 years, the main risk factor for candidiasis infection is cancer (Hope et al., 2010). In 
addition to this, the disease occurs in the case of prolonged treatments that cause severe neutropenia, in 
patients undergoing induction therapy in the course of acute myeloid leukemia and non-Hodgkin's 
lymphoma, in patients who receive transplantation of bone marrow and are under myeloablative therapeutic 
regimens (Arrieta et al., 2011).  An increased risk of invasive candidiasis is observed in children who are 
carriers of inherited immune disorders (Kawaguchi et al., 2009). For this evidence, invasive candidiasis is 
one of the significant causes of morbidity and mortality in neonatal and pediatric age (Kobayashi et al., 
2015). Patients with Candida infections generally present a severe clinical picture, aggravated by low 
immunocompetent defences. For this reason, the medical staff is often forced to treat patients with invasive 
procedures, such as the using of external oxygen, central venous catheters, endotracheal tubes for 
mechanical ventilation, broad-spectrum antibiotics, high doses of corticosteroids (Nguyen et al., 2009). This 
situation may have a heavy economic impact on the economic management of healthcare companies. 
Usually, the days of hospitalization are prolonged for an average period of 21.1 days, attributable to the 
infection, which creates an average increase in hospital costs of $ 39.331 per patient (Leroux et al., 2018). 
Therapies to manage Candida infections vary substantially and the choice of the drug to start the therapy is 
currently based on the anatomic location of the infection, the patients' underlying disease and immune status, 
the specific species of Candida responsible for infection, the susceptibility of the Candida species to 
antifungal drugs and on the recommendations included in specific international guidelines.(Arrieta, 
Maddison, & Groll, 2011; Auriti, Falcone, et al., 2016).  
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In the last ten years, many significant changes have occurred in the management of candidiasis, particularly 
concerning the appropriate use of echinocandins (Benjamin 2016) and expanded-spectrum azoles for 
candidemia and other forms of invasive candidiasis. In 2016 the Infectious Disease Society of America 
(IDSA), published Updated guidelines (Peter G. Pappas, Carol A. Kauffman, David R. Andes, Cornelius J. 
Clancy,Kieren A. Marr, Luis Ostrosky-Zeichner, Annette C. Reboli, Mindy G. Schuster, Jose A. Vazquez, 
Thomas J. Walsh, Theoklis E. Zaoutis, and Jack D. Sobel Clinical Practice Guideline for the Management of 
Candidiasis: 2016 Update by the Infectious Diseases Society of America Clinical Infectious Diseases® 
2016;62(4):e1–50) replacing previous versions. According to guidelines several drugs can be used in the 
treatment of invasive candidiasis in no neutropenic patients: medications belonging to the class of 
echinocandins, caspofungin, anidulafungin, and micafungin, and triazoles, which includes fluconazole, 
which may be administered intravenously or orally (Benjamin et al., 2004). Among echinocandins, 
micafungin shows to have high efficacy against Candida. Unlike other antifungals, micafungin is also able 
to destroy the intraluminal biofilm, that Candida frequently produces in central venous catheters, hindering 
its functioning and generating the persistence of the infection, despite the therapy (Nguyen, MHIMe, & 
Ellis, 2009).  
Although partially studied in the newborn, micafungin is frequently used in the treatment of neonatal 
invasive candidiasis. Micafungin has been approved for use in neonates in Europe but the literature reports 
deep uncertainty about the dosage in neonates. The drug should therefore not be recommended as the first 
choice in newborns. 
Given the high incidence of invasive candidiasis in neonates and considering the unresolved questions on 
the use of micafungin in this population, at Bambino Gesù Children’ Hospital in Rome we carried out a 
phase 2 study, to evaluate the plasma levels of high doses of micafungin and the optimal doses of the drug 
for infants and children up to 90 days of life, suffering from systemic candidiasis. Unlike other clinical trials 
conducted in our and other research Institutes, this study was completed with a careful evaluation of the 
costs, providing evidence on the economic impact generated by a clinical trial for the management of 
severely ill neonates with candidiasis.  
Methodology 
The study was authorized as "non-profit" in 2015 by AIFA and the OPBG Ethics Committee. The American 
pharmaceutical company Astellas (producer of the drug Mycamine), which had previously tried to promote 
a similar pharmacokinetic study unsuccessfully, asked OPBG to acquire the study data, in order to submit 
data to USFDA, to license in the United States the marketing and therapeutic use of micafungin in neonates 
and infants up four months of age. As a first step, we verified the feasibility of the transaction, which 
included the change in the type of clinical study, from a non-profit study to a study for registration and 
market purposes. This phase 2 study was conducted in the Department of Medical and Surgical Neonatology 
(Principal Investigator) and in the Laboratory of Metabolic Pathology (Co-Investigator) of Bambino Gesù 
Children’s Hospital.  
The Bambin Gesù Hospital ranks among those experienced and already active on Candida and use of 
micafungin, therefore, it is considered reliable in terms of collection and analysis of financial and non-
financial information (Auriti, Piersigilli, et al., 2016). In the analysis conducted related to the micro costings 
(Frick, 2009) associated with the clinical results will be presented as foreseen for the first health trials. Very 
often, clinical trials also detect various errors in reporting results and errors in the reporting approach using 
the micro-costing method. The study tries to overcome the possible errors with a correct application 
(Graves, Walker, Raine, Hutchings, & Roberts, 2002). The flanking of qualitative analysis around the case 
guarantees the validity of what is expressed and analysis (Glaser & Strauss, 1967). External validity is 
possible because of the characteristics related to the document. The generalization of research results in 
similar contexts is possible through the analysis of the elements (Eisenhardt, 1989). The analysis and the 
treatment were conducted taking into consideration also reliability as the schola withrs usually would need 
to do when talking about case studies. “Reliability” refers to the absence of random error, enabling 
subsequent researchers to arrive at the same insights if they conducted the study along the same steps again 
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(Denzin & Lincoln, 2002). Transparency and the possibility of replicating the research allow and guarantees 
this aspect and is also confirmed by the verification and authorization supervision of the Italian Drug 
Agency (AIFA). 
Scenario and clinical trial 
An agreement was signed between the Astellas company and the "Bambino Gesù" Children’s Hospital in 
Rome, which provides for the involvement of 48 subjects. In neonates, to obtain an effective therapy using 
Mycamine drug doses up to 5 times those indicated are given without any support of Clinical 
Pharmacokinetic Studies adequate for the number of cases treated. Subjects received treatment for a total of 
16 days on average. The average weight of patients at the beginning of the therapy was 2.86 kg, this 
information is relevant because it is related to the dosage of the drug and therefore, to the cost of the therapy. 
The average days of hospitalization per patient refer to the total period of stay in the hospital and are equal 
to 144 total days. 
Results and discussion 
The data necessary for the evaluation were selected, and the different types of costs were collected in 
quantification as required of the micro-costing approach (Frick, 2009). The Direct variable costs include the 
cost of therapy and study and analysis costs. The Direct fixed costs include the costs of the C.R.O. activity 
and general ethical committee referable to the clinical study in its entirety. The Variable indirect costs 
include ancillary health costs incurred to make patient stay possible. 
The nature of the reported costs was found to be of two categories. Conventional costs derive from internal 
tariffs acquired, then actual costs derive from actually incurred, calculated on time. 
The analysis of the actual costs (direct and indirect) incurred by the Hospital to carry out the Clinical Study 
and gather the results is composed as follows: Accessory healthcare costs are equal to 42%, the costs related 
to the activities carried out by the Ethics Committee are 19%, the costs of study and laboratory analysis are 
equal to 26%, and finally, the personnel costs are equal to 13%. 
If these costs are differentiated by nature it is immediately evident that 60% refers to real costs while 40% 
refers to costs falling within the tariff in terms of recognition of the expense incurred by health institutions 
accredited by the regional health system. 
The fixed direct costs are mainly formed by the activities related to the establishment of practices and ethics 
committee as defined in table 1. 
Table 1 Direct fixed cost 
Cost item Description Value € 
% on the 
total  
Cost C.R.O. 
(Rate for services) 
Tariff C.R.O. for services and documentary activities related to the PK 
study based on tariffs 
market standards 189,360 88.99 
Activity Cost Ethical Committee 
(Rate per service) 
Possible cost for Studio «Profit» 16,000 7.52 
Insurance Cost 
(Cost per service) 
The cost incurred for Clinical Study 7,425 3.49 
Total direct fixed costs   212,785   
The variable direct costs are mainly formed by the study and laboratory analysis which includes the 
involvement of two scholarship holders in the study, preparation and validation costs of the method, 
biologist activities on the first group of patients and the cost of the study fees as shown and quantified in 
table 2. The variable direct costs are also added to the costs of administering therapies formed by the costs 
for drugs and by the hours of the pharmacy for the management of the activity. 
 
 
Table 2 Variable direct costs  
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Cost item Description Value € 
% on 
the 
total  
2 scholarship holders 
(Personal cost x dedicated hours) 
26 monthly payments + meal vouchers 31,900 7.32 
Cost of preparation and validation of the analysis 
method on HPLC 
The average cost of a Department Biologist for 
the study, development, and validation of the 
method 
experimentation of the dosage = 20 days. of 
work. 
Study of the project, data reporting, and 
participation in congresses = 25 days. of work. 18,851 4.33 
Biologist activity 1st patient group 
(Personal cost x no. Hours) 
The average cost of a biologist in the 
department for 16h and 25 'of processing times 
per patient (Dott.ssa Data Godfrey - Metabolic 
Pathology). 5,444 1.25 
Cost of Studio "Fees" 
(Service fee - Fees) 
Price list enhancement, including 
pharmacokinetic analysis, provided by "Ethics 
Committee" and validated 
by C.R.O. based on standard market rates. 235,949 54.16 
Disposable drug cost 
(material cost: unit drug cost x n. doses) 
The 50mg vial can only be used for the clinical 
study. In rare cases of the concomitance of 
 therapy one vial was used for the doses of 2 
patients. 134,176 30.80 
Pharmacy 
(personal cost x no. hours) 
The average cost of nurses and pharmacists for 
the preparation of the drug (€ 12), multiplied 
 for the patient's therapy days. 9,341 2.14 
Total variable direct costs   435,661   
The aforementioned costs are also joined by the variable indirect costs formed mainly by the accessory 
healthcare costs Table 3. 
Table 3 variable indirect costs 
Cost item Description Value € 
% on 
the 
total  
Material cost used in the ward during therapy 
(material cost: consumption x bed x therapy day) 
The average cost of materials consumed per bed 
in the Neonatology Department 
multiplied by the days of patient therapy. 71,980 15.67 
Cost of ward personnel during therapy 
(personal cost x bed x therapy day) 
The average cost of the staff of the Neonatology 
Department per bed multiplied by 
patient therapy days. 293,309 63.85 
Cost of activities carried out by the Cooperatives during 
the therapy 
(cost of cooperatives x bed x therapy days) 
The average cost of Cooperative activities for the 
Neonatology Department for bed 
multiplied by the days of patient therapy. 42,272 9.20 
General costs of the department incurred during the 
therapy 
(indirect costs x bed x therapy days) 
Average Cost General Costs for the Neonatology 
Department for bed multiplied by 
patient therapy days. 31,140 6.78 
Depreciation of machinery used in the treatment period 
(depreciation x bed x therapy days) 
The average cost of amortization of the 
machinery of the Neonatology Dept. for bed 
multiplied by the days of patient therapy. 20,691 4.50 
Total of variable indirect costs    459,393   
 
The most important fixed costs concern the fulfillment of the documentation relating to the technical 
specialty. The variable direct costs that must be taken into greater consideration are those relating to the 
pharmacological study and the costs for the drug itself. If, on the other hand, indirect variable costs are 
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considered, as is frequently reported in the literature, the higher costs are related to personnel (Biancone et 
al., 2019), which account for 63.85% of total indirect costs. 
The total costs of the trial are € 1,107,838. The costs of the clinical trial for each patient , therefore, amount 
to € 23,080 and are made up of health care accessory costs for € 9,571, costs related to the ethics committee 
for € 4.443, study and laboratory analysis for € 6.086, therapy costs for € 2,990.  
According to the analysis by (Arrieta et al., 2011) which considers 1,118 hospital admissions for candidiasis, 
children suffering from this disease have a time of hospitalization equal to 44.8 days against an average 
period of 23.7 days in case of absence. The value of direct and indirect costs for a patient with candidiasis is 
$ 183,645 compared to a cost of $ 91,379 for patients hospitalized but without candidemia (Leroux et al., 
2018). This creates an increase in hospitalization days averaging 21.1 and costs of $ 92,266.  Therefore, the 
identification of an effective dosage and treatment would reduce hospital stay times increasing the 
effectiveness of the therapy reducing costs. 
 In the literature, different individual articles that identify the effects of the drug in new-borns consider a 
birth period between a few days and 24 weeks (Arrieta et al., 2011; Benjamin et al., 2006; Kobayashi et al., 
2015; Makhoul, Sujov, Smolkin, Lusky, & Reichman, 2002; Maximova, Schillani, Simeone, Maestro, & 
Zanon, 2017; Santolaya et al., 2013; Queiroz-Telles et al., 2008) and reflect a level of administration up to 
10 mg / kg / day. 
Only two results concern the analysis and efficacy of micafungin in children under the age of one month 
(Auriti et al., 2016; Santolaya et al., 2013), in these cases the initial dose is set at 2 mg / kg / day with a 
possible increase up to 15 mg / kg / day in order to mitigate the risks deriving from overexposure to 
candidiasis (Schonfeld et al., 2008). The frequency of drug administration in these results is always daily. 
In the trial conducted, therefore, the suggested dosage to have success is equal to 2.86 gr/kg/ day, a dosage is 
consistent with previously held studies. Even the therapeutic frequency is in line with the scientific evidence 
previously expressed. In addition, the evidence is given that with the doses and modalities expressed in the 
scenario the drug was successful and successful in the assessment. 
Conclusions 
The study for the first time tries to classify the costs of a clinical trial on the use of micafungin in neonates 
and young infants. The study provides an example of ways and items of expenses related to the clinical trial. 
The methodology used is applicable and can be used to compare future trials, thus identifying reference 
benchmarks (Minami et al., 2008; Schreyögg, 2008). The study through practical application seeks to 
identify the most correct method to avoid errors during the detection of clinical trials as evidenced by the 
study by Graves et al. (2002) through a correct application. The article also highlights the main cost items to 
be kept under control during the clinical trial phases. Moreover, given the incidence of candida infections in 
neonates and infants, the study increases the literature on the administration and testing of specific drugs for 
treatment and therapy. Future studies may address and compare the results obtained through the use of 
micafungin for the treatment of candida after having adopted the same approach and the same management 
relating to micro-costing. 
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